- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04272216
An Observational Study of Radial Access Embolization Procedures Using HydroPearl Microspheres (RAVI Registry)
July 6, 2023 updated by: Terumo Medical Corporation
The RAVI Registry: A Prospective, Multi-Center, Observational Study of Radial Access Embolization Procedures Using HydroPearl Microspheres
This registry study is designed to collect data on the procedural success and complication rates in real-world patients undergoing HydroPearl embolization procedures via radial access.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
99
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Los Angeles, California, United States, 90095
- University of California - Los Angeles
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Rush University Medical Center
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- SLU Department of Radiology
-
-
New York
-
New York, New York, United States, 11766
- Mount Sinai
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- UNC
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Medical University of South Carolina
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
This is a prospective, multi-center, registry study to assess the procedural success, technical success, and complication rate of radial access procedures using HydroPearl microspheres.
Description
Inclusion Criteria:
- Subject is ≥ 18 years old
- Subject is scheduled for a procedure for treatment with HydroPearl microspheres using radial access.
- Subject is willing and able to complete follow-up requirements
- Subject is willing and able to sign a written Informed Consent form prior to participating in the registry.
Exclusion Criteria:
- Unable to have a procedure with radial access for any reason.
- Participating in another clinical study which, in the opinion of the investigator, could impact the results of this registry.
- Pregnant or planning to become pregnant during the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Treatment with HydroPearl via radial access
all patients will be in the same group/cohort in this open-label, single-arm, observational registry.
|
This is an observational study collecting data on patients who are already being treated with HydroPearl on-label per standard of care.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Procedural Success
Time Frame: During procedure
|
defined as completing the planned procedure without femoral access bailout
|
During procedure
|
Technical Success
Time Frame: End of procedure
|
delivery of HydroPearl to the target vessel and slowing the blood flow with microsphere embolization
|
End of procedure
|
Freedom from major adverse events and radial access complications
Time Frame: within 30 days post-procedure
|
within 30 days post-procedure
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Marcelo Guimaraes, MD, Medical University of South Carolina
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 6, 2020
Primary Completion (Actual)
March 7, 2022
Study Completion (Actual)
March 11, 2023
Study Registration Dates
First Submitted
February 13, 2020
First Submitted That Met QC Criteria
February 14, 2020
First Posted (Actual)
February 17, 2020
Study Record Updates
Last Update Posted (Actual)
July 10, 2023
Last Update Submitted That Met QC Criteria
July 6, 2023
Last Verified
October 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Congenital Abnormalities
- Prostatic Diseases
- Cardiovascular Abnormalities
- Vascular Malformations
- Neoplasms, Muscle Tissue
- Urogenital Diseases
- Male Urogenital Diseases
- Genital Diseases, Male
- Genital Diseases
- Prostatic Hyperplasia
- Hyperplasia
- Arteriovenous Malformations
- Leiomyoma
Other Study ID Numbers
- TIS2019-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Benign Prostatic Hyperplasia
-
St. Joseph's Healthcare HamiltonOntario Ministry of Health and Long Term CareCompletedBenign Prostatic HyperplasiaCanada
-
San Carlo di Nancy HospitalElesta S.R.L.CompletedBenign Prostatic Hyperplasia | Benign Prostatic Hypertrophy | Benign Prostatic Hypertrophy With Outflow Obstruction | Prostate HyperplasiaItaly
-
GlaxoSmithKlineCompletedBenign Prostatic Hyperplasia
-
Catholic University of the Sacred HeartCompletedBenign Prostatic Hyperplasia (BPH) | Benign Prostatic Enlargement (BPE)Italy
-
Boston Scientific CorporationCompletedProstatic Hyperplasia | Benign Prostatic Hyperplasia | Prostatic Hyperplasia, Benign | Prostatic Hypertrophy | Prostatic Hypertrophy, Benign | Adenoma, Prostatic | Prostatic Adenoma | RezumDominican Republic, Czechia, Sweden
-
Boston Scientific CorporationCompletedBenign Prostatic Hyperplasia | Prostatic Hyperplasia, Benign | Prostatic Hypertrophy | Prostatic Hypertrophy, Benign | Adenoma, Prostatic | Prostatic Adenoma | RezumDominican Republic
-
IMBiotechnologies Ltd.CompletedBenign Prostatic Hyperplasia | Benign Prostatic HypertrophyCanada
-
IRCCS Policlinico S. MatteoCompletedBenign Prostatic Hyperplasia | Benign Prostatic Hypertrophy With Outflow ObstructionItaly
-
American Medical SystemsCompletedBenign Prostatic Hyperplasia | BPH | Benign Prostatic Hypertrophy | Prostate Disease
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Not yet recruitingLower Urinary Tract Symptoms | Benign Prostate Hyperplasia | Benign Prostatic Hypertrophy With Outflow Obstruction
Clinical Trials on Treatment with HydroPearl via radial access
-
Minneapolis Heart Institute FoundationRecruitingPatient Satisfaction | Vascular Access ComplicationUnited States
-
Centre Hospitalier Universitaire de NīmesCompletedUltrasonography | Radial ArteryFrance
-
Universitat Jaume IRecruiting
-
AstraZenecaCompletedHealthy Subjects | BioavailabilityGermany
-
Centre Hospitalier Universitaire de NīmesCompletedErectile DysfunctionFrance